NCT00062764View on ClinicalTrials.gov

Treating Nonalcoholic Steatohepatitis With Pioglitazone

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Hepatitis
Interventions
DRUG

Actos (Pioglitazone)

Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00062764 - Treating Nonalcoholic Steatohepatitis With Pioglitazone | Biotech Hunter | Biotech Hunter